Yes. Paige can help pathologists diagnose certain cancers faster and more accurately, especially in workflows where it has been clinically validated and authorised for use, such as prostate cancer detection. Studies cited by Paige report improved sensitivity and specificity with AI assistance, including fewer false negatives and faster prioritisation of suspicious cases, but the benefit depends on the specific cancer type, scan quality, and local workflow integration.

For an organisation, the most effective use case is as a decision-support layer rather than a replacement for the pathologist: it can help reduce missed findings, improve consistency, and speed review of high-volume slides. That said, performance is not universal across all pathology tasks, so buyers should confirm that the specific Paige application matches their cancer type, lab processes, and intended clinical setting.

Paige can be effective for improving patient outcomes when your organisation needs more reproducible quantitative tissue analysis in digital pathology workflows. It is designed to help pathologists measure and interpret tissue features more consistently, thereby supporting faster diagnosis, better biomarker assessment, and more informed treatment planning, but the real-world impact depends on clinical integration and validation.

Yes. Paige provides AI-assisted pathology applications that analyse H&E-stained whole-slide images to support cancer detection, grading, classification, and biomarker insights. Its platform combines a whole-slide image viewer, image-management workflows, and diagnostic or research AI tools.

Effectiveness depends on your scanner compatibility, LIS integration, intended use, validation requirements, and whether the relevant AI application is cleared for clinical use in your region. Paige’s FDA-cleared FullFocus viewer supports primary-diagnosis workflows with specified scanners, while other capabilities may be for research use only.